Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "ANDA"

2589 News Found

Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
R&D | January 14, 2026

Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery

Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs


GEA to power new biotechnology fermentation hub in Netherlands
Biotech | January 14, 2026

GEA to power new biotechnology fermentation hub in Netherlands

BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities


AbbVie strikes deal with Trump administration on drug prices, US investment
News | January 13, 2026

AbbVie strikes deal with Trump administration on drug prices, US investment

AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing


Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer
Clinical Trials | January 12, 2026

Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer

The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population


Aragen slashes drug development time with CHOMax platform
News | January 12, 2026

Aragen slashes drug development time with CHOMax platform

CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes


MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy
Clinical Trials | January 12, 2026

MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy

MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms


Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial
Clinical Trials | January 11, 2026

Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial

DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases


Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
Biotech | January 11, 2026

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism


Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera
News | January 11, 2026

Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories